INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2017. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $133,126,068 | +55.3% | 1,943,730 | +62.4% | 0.02% | +33.3% |
Q4 2023 | $85,743,679 | +70.0% | 1,197,203 | +50.3% | 0.02% | +50.0% |
Q2 2023 | $50,439,699 | -2.7% | 796,584 | -16.8% | 0.01% | -9.1% |
Q1 2023 | $51,831,351 | -6.0% | 957,181 | -8.1% | 0.01% | -15.4% |
Q4 2022 | $55,135,972 | +37.3% | 1,041,874 | +20.7% | 0.01% | +18.2% |
Q3 2022 | $40,152,272 | -12.1% | 862,933 | +7.8% | 0.01% | -8.3% |
Q2 2022 | $45,677,128 | +17.0% | 800,230 | +25.4% | 0.01% | +33.3% |
Q1 2022 | $39,035,671 | +27.9% | 637,942 | +9.4% | 0.01% | +50.0% |
Q4 2021 | $30,525,000 | +129.0% | 583,207 | +63.1% | 0.01% | +100.0% |
Q3 2021 | $13,331,000 | -23.8% | 357,588 | -16.5% | 0.00% | -25.0% |
Q2 2021 | $17,491,000 | +83.4% | 428,485 | +52.5% | 0.00% | +100.0% |
Q1 2021 | $9,536,000 | -43.1% | 281,035 | -46.7% | 0.00% | -50.0% |
Q4 2020 | $16,768,000 | +86.4% | 527,281 | +50.4% | 0.00% | +100.0% |
Q3 2020 | $8,997,000 | -43.2% | 350,623 | -43.2% | 0.00% | -60.0% |
Q2 2020 | $15,844,000 | +72.5% | 617,235 | +3.3% | 0.01% | +66.7% |
Q1 2020 | $9,183,000 | +19.6% | 597,440 | +166.9% | 0.00% | +50.0% |
Q4 2019 | $7,679,000 | +262.6% | 223,810 | -21.1% | 0.00% | +100.0% |
Q3 2019 | $2,118,000 | -50.6% | 283,505 | -14.1% | 0.00% | 0.0% |
Q2 2019 | $4,284,000 | +6.6% | 330,070 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $4,020,000 | +6.9% | 330,070 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $3,759,000 | -47.5% | 330,070 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $7,163,000 | +22.8% | 330,070 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $5,832,000 | -7.4% | 330,070 | +10.3% | 0.00% | 0.0% |
Q1 2018 | $6,301,000 | +55.9% | 299,320 | +7.3% | 0.00% | +100.0% |
Q4 2017 | $4,041,000 | -8.2% | 279,070 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $4,404,000 | +109.7% | 279,070 | +65.1% | 0.00% | +100.0% |
Q2 2017 | $2,100,000 | -52.7% | 169,070 | -38.1% | 0.00% | -50.0% |
Q1 2017 | $4,442,000 | +4.8% | 273,354 | -2.7% | 0.00% | 0.0% |
Q4 2016 | $4,238,000 | +3.7% | 280,850 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $4,088,000 | -46.5% | 280,850 | +42.6% | 0.00% | -50.0% |
Q2 2016 | $7,648,000 | – | 197,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |